Cargando…
2370. Dalbavancin Use in Emergency Department and Observation Unit to Prevent Inpatient Admission for Acute Bacterial Skin and Skin Structure Infection (ABSSI)
BACKGROUND: ABSSSIs are a common cause of hospitalization. Dalbavancin (DBV) is a lipoglycopeptide antibiotic approved as a single 1,500 mg intravenous (IV) dose for the treatment of patients with ABSSSI. DBV offers a unique opportunity for cost avoidance by shifting more ABSSI treatment to the outp...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255046/ http://dx.doi.org/10.1093/ofid/ofy210.2023 |